The MarketWatch News Department was not involved in the creation of this content. NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA ...
In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of 11.5 months achieved a DCR of 89.3% and Median PFS of 8.6 months ...
IIT Guwahati Research: GLOFs cause significant socio-economic and environmental damage, including loss of life, destruction ...
Type 2 diabetes affects hundreds of millions globally and remains one of the most pressing non-communicable disease challenges in India. Traditionally, clinical focus has centred on insulin resistance ...
CHENNAI: The state government has informed the Madras High Court that experts from the Indian Institute of Technology-Madras ...
NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in ...
NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results